NEXTBio Capital Management LP
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 13, 2026), NEXTBio Capital Management LP reported 23 stock positions worth $170.5 million. Its top holding was Terns Pharmaceuticals (TERN) at 13.1% of the portfolio, followed by Protagonist Therapeutics (PTGX, 11.8%) and Vor Biopharma (VOR, 7.7%).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0002038158
- Portfolio Value
- $170.5M (Q4 2025)
- SEC Filing
- 0001172661-26-000761 ↗ filed Feb 13, 2026
Holdings Value
Holdings 23 stocks · $170.5M
| TERN Terns Pharmaceuticals Inc. | 13.06% | 551,190 | $22.3M | — |
| PTGX Protagonist Therapeutics Inc. | 11.76% | 229,619 | $20.1M | — |
| VOR Vor Biopharma Inc. | 7.67% | 999,967 | $13.1M | — |
| ZBIO Zenas Biopharma Inc. | 6.86% | 321,983 | $11.7M | — |
| STTK Shattuck Labs Inc. | 6.74% | 3,149,907 | $11.5M | — |
| VSTM Verastem Inc. | 5.92% | 1,307,330 | $10.1M | — |
| PVLA Palvella Therapeutics Inc. | 5.08% | 82,686 | $8.7M | — |
| XENE Xenon Pharmaceuticals Inc. | 4.83% | 183,704 | $8.2M | — |
| RYTM Rhythm Pharmaceuticals Inc. | 4.24% | 67,586 | $7.2M | — |
| GPCR Structure Therapeutics Inc. | 3.85% | 94,443 | $6.6M | — |
| IVA Inventiva SA - ADR | 3.54% | 1,298,701 | $6.0M | — |
| CMPX Compass Therapeutics Inc. | 3.51% | 1,114,005 | $6.0M | — |
| CMPS Compass Pathways PLC | 3.05% | 752,631 | $5.2M | — |
| ORIC Oric Pharmaceuticals Inc. | 2.95% | 615,720 | $5.0M | — |
| CBIO Crescent Biopharma Inc. | 2.59% | 372,856 | $4.4M | — |
| PCVX Vaxcyte Inc. | 2.58% | 95,485 | $4.4M | — |
| EVMN Evommune Inc. | 2.29% | 228,286 | $3.9M | — |
| COGT Cogent Biosciences Inc. | 2.00% | 95,819 | $3.4M | — |
| IRON Disc Medicine Inc. | 1.99% | 42,778 | $3.4M | — |
| OCS Oculis Holding AG | 1.75% | 149,750 | $3.0M | — |
| ZLAB Zai Lab Ltd.-ADR | 1.69% | 163,362 | $2.9M | — |
| KALV Kalvista Pharmaceuticals Inc. | 1.25% | 131,796 | $2.1M | — |
| ACET Adicet Bio Inc. | 0.78% | 157,827 | $1.3M | — |
Portfolio Sells Q4 2025
No earlier filing to compare with.
Portfolio Buys Q4 2025
No earlier filing to compare with.